CN101234169B - Application of Chinese medicine composition in preparing medicament for adjusting cardiac muscle cell potassium ion channel - Google Patents
Application of Chinese medicine composition in preparing medicament for adjusting cardiac muscle cell potassium ion channel Download PDFInfo
- Publication number
- CN101234169B CN101234169B CN2007100030399A CN200710003039A CN101234169B CN 101234169 B CN101234169 B CN 101234169B CN 2007100030399 A CN2007100030399 A CN 2007100030399A CN 200710003039 A CN200710003039 A CN 200710003039A CN 101234169 B CN101234169 B CN 101234169B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine composition
- chinese medicine
- current
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 120
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 102000004257 Potassium Channel Human genes 0.000 title claims abstract description 16
- 108020001213 potassium channel Proteins 0.000 title claims abstract description 16
- 210000004413 cardiac myocyte Anatomy 0.000 title description 6
- 230000002107 myocardial effect Effects 0.000 claims abstract description 29
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000011591 potassium Substances 0.000 claims abstract description 23
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 15
- 230000036982 action potential Effects 0.000 claims abstract description 13
- 230000008569 process Effects 0.000 claims abstract description 8
- 230000003288 anthiarrhythmic effect Effects 0.000 claims abstract description 7
- 230000002336 repolarization Effects 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 34
- 239000000843 powder Substances 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 241001489978 Eupolyphaga Species 0.000 claims description 12
- 206010003119 arrhythmia Diseases 0.000 claims description 12
- 230000006793 arrhythmia Effects 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 241000208340 Araliaceae Species 0.000 claims description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 10
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 10
- 210000000170 cell membrane Anatomy 0.000 claims description 10
- 235000008434 ginseng Nutrition 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- -1 filters Substances 0.000 claims description 8
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 206010047302 ventricular tachycardia Diseases 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- 210000004165 myocardium Anatomy 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 206010022998 Irritability Diseases 0.000 claims description 4
- 206010042600 Supraventricular arrhythmias Diseases 0.000 claims description 4
- 208000008131 Ventricular Flutter Diseases 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 3
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 230000001052 transient effect Effects 0.000 abstract description 7
- 230000001419 dependent effect Effects 0.000 abstract description 5
- 206010001497 Agitation Diseases 0.000 abstract 1
- 230000001934 delay Effects 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 description 30
- 239000000243 solution Substances 0.000 description 15
- 230000028161 membrane depolarization Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 12
- 230000010412 perfusion Effects 0.000 description 11
- 230000002861 ventricular Effects 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 241000700199 Cavia porcellus Species 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000107 myocyte Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 3
- 206010003662 Atrial flutter Diseases 0.000 description 3
- 235000019743 Choline chloride Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960003178 choline chloride Drugs 0.000 description 3
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000005405 multipole Effects 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 2
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102100023336 Chymotrypsin-like elastase family member 3B Human genes 0.000 description 2
- 102000002734 Collagen Type VI Human genes 0.000 description 2
- 108010043741 Collagen Type VI Proteins 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 206010003668 atrial tachycardia Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 210000000080 chela (arthropods) Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000037024 effective refractory period Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 108010043524 protease E Proteins 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- YTDJTZGUTCBZCT-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;potassium Chemical compound [K].OC(=O)[C@@H](N)CC(O)=O YTDJTZGUTCBZCT-DKWTVANSSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 208000010271 Heart Block Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000004301 Sinus Arrhythmia Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000018452 Torsade de pointes Diseases 0.000 description 1
- 208000002363 Torsades de Pointes Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000003715 calcium chelating agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940089027 kcl-40 Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940126121 sodium channel inhibitor Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an application of a Chinese traditional medicine composition in regulation of potassium ion channel in myocardial cells. The Chinese traditional medicine composition inhibits an inward rectifier potassium current, a transient outward potassium current and delays an outward rectifier potassium current in a voltage dependent mode, which prolong the action potential duration (APD) to play a role of anti-arrhythmic effect through lowering the excitability of myocardial cells and inhibiting the repolarization process of the action potential (AP) of the myocardial cells.
Description
Technical field
The present invention relates to application and the application in preparation treatment antiarrhythmic medicament of a kind of Chinese medicine composition in cardiac muscle cell potassium ion channel is regulated.
Background technology
Cardiovascular disease has become the healthy principal disease of harm humans like hypertension, coronary heart disease, arrhythmia etc., and its M & M is high to occupy first place in the world.Serious arrhythmia, like quick type ventricular tachycardia (VT), quiver (VF) in the chamber and heart broken dead (SCD) then is the dead major reason of cardiovascular disease.
The normal blood-pumping function of heart depends on the alternating activity of the contraction and the diastole of myocardium rhythmicity, and formation that myocardial cell membrane is excited and conductive process then are the initiating agents that triggers contraction of cardiac rhythm property and diastole.Formation that cardiac muscle is excited and conduction are the bases that is changed to the myocardial cell transmembrane potential.The variation abnormality of transmembrane potential will cause the rhythm of the heart to change, and be called arrhythmia.Arrhythmia has a strong impact on the blood-pumping function of heart, in time treatment.
Arrhythmia can be divided into sinus arrhythmia, atrial arrhythmia, atrioventricular junction arrhythmia, ventricular arrhythmia and heart block according to the arrhythmia happening part, and atrial arrhythmia comprises: atrial premature beat, atrial tachycardia, atrial flutter, atrial fibrillation; Ventricular arrhythmia comprises: premature ventricular beat, ventricular tachycardia, ventricular flutter, ventricular fibrillation [the 2nd edition P172-212 in Ye Rengao internal medicine People's Health Publisher October in 1984].
At present clinical use and develop in antiarrhythmic drug classify with mechanism of action according to influence to cardiac electrophysiology; Can be divided into four big types: the I class is a sodium channel inhibitor; The II class is a beta-blocker; The III class is the medicine that selectivity prolongs myocardial cell action potential duration, APD (APD) and effective refractory period (ERP), and selectivity blocks the medicine of myocardium potassium-channel, and the IV class is a calcium channel blocker.The I class, the II class, IV class medicine all has the effect that reduces conduction velocity even cause conduction block, and these effects can increase the probability of reciprocal excitation, and bring out arrhythmia.III class medicine does not have obvious influence [the 4th edition the 14th printing P159-171 in Li Duan pharmacology (the 4th edition) People's Health Publisher November in 1999] to self-disciplining.
Patent ZL02146572.X discloses a kind of pharmaceutical composition of treating Coronary heart disease ventricular early throb and preparation method thereof.Unexposed this pharmaceutical composition of this patent is for the regulating action of potassium-channel, and application only limits to the treatment of Coronary heart disease ventricular early throb, and the present invention has done further research on the basis of patented technology once more.Confirm that Chinese medicine composition of the present invention has inhibitory action to potassium-channel, can be applied to various room property, chamber property and supraventricular arrhythmia.
Summary of the invention
The purpose of this invention is to provide the application of a kind of Chinese medicine composition in cardiac muscle cell potassium ion channel is regulated, the mode that this Chinese medicine composition can voltage relies on suppresses the inward rectification potassium current, instantaneous export-oriented potassium current, and Delayed Rectifier Potassium Current.Through irritability that reduces myocardial cell and the process of repolarization that suppresses myocardial cell action potential (AP), over reach current potential time-histories (APD) is brought into play antiarrhythmic effect.
Another object of the present invention provides the method for preparing of the active component in the application of this Chinese medicine composition in cardiac muscle cell potassium ion channel is regulated.
Another object of the present invention provides the application of this Chinese medicine composition in preparation treatment antiarrhythmic medicament.
Based on the foregoing invention purpose, the invention provides the application of a kind of Chinese medicine composition in cardiac muscle cell potassium ion channel is regulated, it is characterized in that this Chinese medicine composition is processed by following bulk drugs:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
The weight ratio of crude drug is preferably in the Chinese medicine composition of the present invention:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
In the application of the present invention, the active component of this Chinese medicine composition is processed by the following step:
A) people participates in 70% alcohol reflux three times, and merge extractive liquid, filters, and concentrates oven dry, the fine powder that is ground into;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters spissated extractum;
C) fine powder that is broken into of Eupolyph aga sinesis Walker;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decocte with water 2 times, merge extractive liquid,, spissated extractum.
E) with step b) and d) merging of gained extractum, the fine drug powder of adding step c) gained, oven dry is ground into fine powder, adds step a) gained fine drug powder, and mixing promptly gets this Chinese medicine composition active component.
In the application of the present invention; Said Chinese medicine composition is a kind of in capsule, tablet, electuary, powder or the oral liquid formulations; For above-mentioned dosage form can be realized; Need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary; For example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic etc.; Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc., and disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc., lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc., and sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence, antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene.
During the present invention used, the mode that this Chinese medicine composition can voltage relies on suppressed myocardial cell inward rectification potassium current, instantaneous export-oriented potassium current, and Delayed Rectifier Potassium Current.
During the present invention used, this Chinese medicine composition reduced the irritability and the process of repolarization that suppresses myocardial cell AP of myocardial cell through the adjusting to the myocardial cell membrane potassium channel.
During the present invention used, this Chinese medicine composition can prolong the myocardial cell action potential duration, APD through the adjusting to the myocardial cell membrane potassium channel.
Among the present invention, the application of this Chinese medicine composition in preparation treatment antiarrhythmic drug.
During the present invention used, said arrhythmia comprised: supraventricular arrhythmia or ventricular tachycardia or ventricular flutter or ventricular fibrillation.
During the present invention used, said arrhythmia comprised: atrial premature beat or atrial tachycardia or atrial flutter or atrial fibrillation.
Among the present invention, this Chinese medicine composition is to myocardial cell membrane I
K1Inhibitory action is arranged, reduce I
K1Electric current density.
Among the present invention, this Chinese medicine composition is to myocardial cell membrane export-oriented potassium current (I of moment
To) electric current has inhibitory action, can quicken the inactivation of electric current.
Among the present invention, this Chinese medicine composition to interior to rectification potassium current I
K1(I
K1) the interior of electric current have inhibitory action to composition, but do not change the upset current potential and the rectification characteristic of passage, and slightly increase the export-oriented composition of electric current, help stabilizing cell membrane, eliminate early after depolarization.
The consumption of Chinese medicine composition of the present invention by active component crude drug gross weight, is 7-28 gram/day, but takes every day once, preferably divides and takes for 2-4 time.
Description of drawings
Fig. 1 isolated heart perfusion system (Langendorff perfusion system).
Fig. 2 Chinese medicine composition of the present invention is to I
K1Electric current influence A, contrast; When B, drug level 0.5% to I
K1Inhibitory action is arranged; C, Chinese medicine composition of the present invention is to I
K1The influence of electric current density-voltage relationship.
Fig. 3 I
ToCurrent characteristic and Chinese medicine composition of the present invention are to the effect A of electric current; The outward current that on single rat ventricular myocytes, records, Vh=-90mV gives earlier-the preceding stimulation of 40mV 20ms; Again with step 10mV depolarization to+60mV; Clamp down on time 400ms, activated outward current has two kinds of compositions, comprises transient current and keeps electric current.When B, drug level 0.5% the Ito electric current there is inhibitory action.C, the Ito current-voltage relation curve.● be total peak point current, ▲ for keeping electric current, ■ be transient current (■=●-▲).D, the electric current density-voltage curve of transient current peak value.● before medication, ▲ for after the medication, medicine has inhibitory action to Ito, and show as electric current density and reduce.
Fig. 4 Chinese medicine composition of the present invention is to I
ToThe time dependence inactivation influence A, before the administration; B, drug level 0.5%; And to I
ToThe inactivation of electric current partly carries out match with the single index equation.
Fig. 5 Chinese medicine composition of the present invention is to I
ToThe stable state inactivation influence A, before the administration; B, drug level 0.5%; C, the voltage-dependent of outward current heterogeneity inactivation, ● be peak point current; ▲ for keeping electric current; ■ be transient current (■=●-▲) D, the stable state inactivation curve of instantaneous outward current Ito before and after the medication, ● before medication; ▲ for after the medication, solid line is respectively the curve result with the Bolziman equation model among the figure.
Fig. 6 Chinese medicine composition of the present invention is to I
ToThat recovers behind the electric current inactivation influences A, contrast; B gives drug level 0.5%; C, I
ToTime dependence recovery curve behind the inactivation, ● before medication, ▲ for after the medication, solid line is respectively the curve with the single index equation model among the figure.
Fig. 7 Chinese medicine composition of the present invention is to Delayed Rectifier Potassium Current (I
K) the voltage-dependent inhibitory action A of electric current, V
H=-40mV, progressively depolarization continues 5s to 60mV, the single myocyte of guinea-pig ventricular, can draw a voltage and rely on and the activated outward current I of time-dependent
KWhen B, drug level 0.5%, the medication front and back are at V
T=50mV continues the change C of 5s recorded current, before and after the medication, and the I-V relation curve that obtains with the current density versus voltage mapping of the tail current peak value that writes down under each test voltage.
Fig. 8 Chinese medicine composition of the present invention is to the activated I of time dependence
KThe inhibitory action A of electric current, V
H=-40mV, V
T=50mV continues 500ms～5s, increases progressively with 500ms, can record with the stimulation time prolongation the single myocyte of guinea-pig ventricular to increase I gradually
KElectric current and tail current.When B, drug level 0.5%, the I of record under same test voltage and time
KElectric current and tail current.C is before and after the medication, with the tail current peak value time dependence activating curve that mapping obtains to activationary time of record under the different activationary times.
The specific embodiment
Following embodiment is used to illustrate the preparation of Chinese medicine composition of the present invention, but it can not constitute any restriction to scope of the present invention.
Embodiment 1
Application for the ease of the potassium-channel regulating action of this Chinese medicine composition is prepared as capsule with this Chinese medicine composition
Prescription:
Radix Ginseng 89g 112g Radix Ophiopogonis Fructus Corni 224g Radix Salviae Miltiorrhizae 224g
Semen Ziziphi Spinosae (parched) 186g Herba Taxilli 186g Radix Paeoniae Rubra 89g Eupolyphaga Seu Steleophaga 75g
Radix Et Rhizoma Nardostachyos 89g Rhizoma Coptidis 45g Fructus Schisandrae Sphenantherae 67g Os Draconis 149g
Method for preparing:
A) in the above-mentioned prescription, Radix Ginseng is with 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and reclaims ethanol, concentrates, and oven dry is ground into fine powder, and is subsequent use;
B) in the above-mentioned prescription, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos are with 70% alcohol reflux three times, and merge extractive liquid, filters, and reclaims ethanol, concentrate extractum, subsequent use;
C) in the above-mentioned prescription, Eupolyph aga sinesis Walker is broken into fine powder, and is subsequent use;
D) in the above-mentioned prescription, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decocte with water secondary, merge extractive liquid, filters, the extracting solution of filtrating and Fructus Schisandrae Sphenantherae etc. merges, concentrate extractum, subsequent use;
E) with step b) and d) merging of gained extractum, the fine drug powder that adds the step c) gained is dried, and is ground into fine powder, adds step a) gained fine drug powder, mixing, 1000 capsules of packing into.
Indication: be used for supraventricular arrhythmia, ventricular tachycardia, atrial flutter.
Usage and consumption: oral.One time 2～4,3 times on the one.
Test Example
Chinese medicine composition pharmacological activity test of the present invention.
For the activity of the regulating action of illustrating Chinese medicine composition of the present invention sodium channel, use the capsule 's content dry powder (to call capsule dry powder of the present invention in the following text) that makes by the foregoing description 1 method to carry out following animal experiment.
1. material and method
1.1. material
1) reagent capsule dry powder of the present invention is provided by Yiling Pharmaceutical Co., Ltd, Shijiazhuang.II Collagen Type VI enzyme (collagenase II) is the Gibico Company products.Chain protease E is the Merck Company products.N-2-hydroxyethyl piperazine-N '-2-ethanesulfonic acid (HEPES), ethylene glycol-two tetraacethyls (EGTA), glutamic acid (L-Glutamic acid), taurine (Taurine), aspartic acid, phosphagen disodium, choline chloride (Choline-Cl), CaCl
2, K
2ATP is the Sigma Company products.4-aminopyridine (4-AP) is the Fluka Company products.All the other reagent are homemade analytical pure, and chemical reagents corporation provides by Beijing.
2) solution
1. there are not calcium tyrode's solution (mmol/L): NaCl 136, KCl 5.4, MgCl
21.0, NaH
2PO4 0.33, HEPES 10, Glucose 10 transfer pH complete 7.4 with NaOH.
2. KB liquid (mmol/L): KCl 40, KH
2PO4 20, MgSO
43.0, KOH 80, L-glutamic acid 50, taurine 20, HEPES 10, Glucose 10, EGTA 0.5, transfer pH to 7.4 with KOH.
3. write down the perfusate (mmol/L) of full cell potassium current: Choline-Cl 136, MgCl
21.2, KCl 5.4, NaH
2PO4 0.33, CaCl
21.8, CdCl
20.15 HEPES 10, Glucose 10 transfer pH to 7.4 with LiOH.Record I
KThe time add 1mmol/LBaCl
2With blocking-up I
K1Electric current.
4. write down the interior liquid (mmol/L) of electrode of full cell potassium current: Aspartic acid potassium 120, KCl 20, HEPES 5, MgCl
21.0, K
2-ATP 4, EGTA 10, phosphagen disodium 2 are transferred pH to 7.3 with KOH.Liquid all passes through diameter 0.22 μ m filtering with microporous membrane in the electrode used therein.
The preparation of capsule dry powder solution 5. of the present invention: with capsule dry powder of the present invention, the extracellular perfusate with no KCl is mixed with mass percent concentration 5% solution earlier, adjusts K+ concentration again to 5.4mmol/L, and the centrifuging and taking upper solution is subsequent use.
3) animal male SD rat, body weight 250-300g.Provide by Beijing Vital River Experimental Animals Technology Co., Ltd..
1.2 method
1.2.1. the separation of single myocardial cell prepares the ventricular muscles individual cells with acute enzymatic isolation method.Get rat with 50mg/kg pentobarbital sodium intraperitoneal injection of anesthesia after, open breast and take out heart, in 4 ℃ of no calcium Tyrode liquid, remove fat and pericardium, separation aorta and intubate are carried out Langendorff cardiac perfusion (see figure 1), speed is 6～8ml/min.With no calcium Zinciodati Comp solution perfusion 3min (perfusion pressure is the 20cm water column), clean the arteria coronaria inner blood earlier, reuse hangs down calcium enzymolysis solution (CaCl
2For the low calcium tyrode's solution of 0.05mmol/L, contain II Collagen Type VI enzyme 0.4mg/ml, protease E 0.04mg/ml) the circulation perfusion; After about 20 minutes, heart is taken off from the Langendorff device, insert in the room temperature KB liquid; Cut off the tissue of atrium and basilar part, hold the ophthalmology tweezer, slowly blow and beat with the suction pipe of thick opening with ventricular organization's tearing gently; Myocardial cell is broken away from from cardiac muscular tissue; Obtain single ventricular muscle cell, supernatant filters with 120 purpose nylon drainage screens, and myocardial cell is collected in the test tube that contains KB liquid.Whole perfusion system temperature remains on 37 ℃, and all perfusates and KB liquid all pass to 100% O
2Saturated more than 30 minutes.Cell is at room temperature left standstill about half an hour multiple calcium to 0.25mmol/L, and room temperature preservation is subsequent use.The separation method of guinea pig myocardium cell is basic identical.
1.2.2 draw a little KB suspension that is rich in cell in the perfusion groove of 0.5ml before the experiment of full cell patch pincers experimental record, leave standstill 5～10min, treat cell sink to the bottom attach wall after, use 100%O
2Saturated extracellular fluid carries out perifusion 5～10min, the about 2ml/min of flow velocity.Select clear-cut margin down at inverted microscope (OLYMPUS IX70), smooth surface, band is clear, shrinkage-free cell.Experiment is carried out under 22～24 ℃ of room temperatures.The recording method of the full cell patch pincers of employing standard, recording channel electric current under the voltage clamp pattern.Patch clamp amplifier (Axopatch 700B, U.S. Axon company) is connected with computer through A/D and D/A data converter (Digidata 1322, U.S. Axon company).The collection of stimulus signal and voltage, current input signal is controlled by software (pClampex 10.0, U.S. Axon company).Glass fiber embryonic tube (Inst. of Physics, CAS provides) draws appearance (p-97, U.S. sutter company) through microelectrode and is drawn by 4 steps and form, through polishing appearance (MF-830, Japanese NARISHIGE company) polishing rear tip diameter 2～3 μ m.Charge that to go into water resistance behind the liquid in the electrode be 1.5～3M Ω, behind the compensation liquid junction potential, regulate Three dimensional steerable device (MHW-3, Japanese NARISHIGE company) and make eletrode tip shift to cell surface, form high resistant sealing-in (giga seal), sealing-in resistance is more than the 1G Ω.Compensate fast electric capacity and inhale the broken cell film and form full cell record pattern.Electric capacity gives when measuring-stimulation of 10mV step, and V asks membrane capacitance with Cm=τ Iss/ Δ.Regulate the compensation 80%～90% of slow capacitance compensation and series resistance to reduce instantaneous charging and discharging currents and clamper error.Signal is the quadravalence Bezier low pass filter of 1kHz through cut-off frequency, and sample rate is 10kHz.
When record, for avoiding the relaxation phenomenon influence of electric current, add ATP in the liquid in the electrode, and the control experiment is accomplished in 25 minutes behind the cell rupture of membranes.According to experimental design, with the drug solution for preparing, distinguish perfusion with the speed of 2ml/min to cell perfusion groove with the constant current peristaltic pump, use whole negative pressure suction device that waste liquid is absorbed from the perfusion groove simultaneously.Recording method is to stablize the preceding current value of 5min record administration, the current value behind the administration 5min under the record drug effect behind the rupture of membranes.Sampling back data-storing supplies to measure and analyze and use in computer hard disc.For eliminating the iuntercellular error, current value is represented with electric current density (pA/pF).
1.2.3 each galvanism scheme is set and observation index 1) record I
K1The time stimulation protocol: keep current potential (Vh)-40mV, command potential-120mV～0mV, step 10mV clamps down on time 400ms, stimulus frequency 0.2Hz; I with test voltage-100mV
K1The variation of steady-state current density before and after medication is as observation index; 2) record I
ToStimulation protocol during current-voltage correlation: keep current potential (Vh)-90mV, give earlier-the preceding stimulation of 40mV 20ms, give again-40mV～+ depolarization of 60mV stimulates, and step 10mV clamps down on time 400ms, stimulus frequency 0.2Hz; I with test voltage 60mV
ToThe variation of peak current density before and after medication is as observation index; 3) record I
ToThe stimulation protocol of stable state inactivation: keep voltage-90mV, give 400ms preceding stimulation, clamp down on then at 60mV 300ms record I from-120mV to 60mV step 10mV
ToElectric current, and relatively change before and after the medication; 4) record I
ToThe stimulation programs that time dependence recovers behind the inactivation: adopt dipulse to stimulate, keep voltage-90mV, successively giving two depolarizations then stimulates P1 to the depolarization that 60mV continues 200ms, and P2, its interval Δ t increase successively and be made as 1,3 respectively; 5,7,10,15,20; 30,40,60,90,120; 150,180,210,250,300 (ms).The corresponding peak current I of record P2.With I/Imax Δ t is made recovery curve behind the stable state inactivation.5) voltage-dependent of measuring Ik activates: V
H=-40mV, from-40mV gradually depolarization to+60mV, step 10mV, stimulus wave is wide to be 5s, gets back to V
HContinue 2.5s record tail current.6) time dependence of measuring the Ik tail current activates (envelope of tails test): V
H=-40mV, depolarization is back to V to+50mV
H, continuous 10 pulses, the wide 500～5000ms that is respectively of each impulse stimulation ripple does not wait, and increases progressively gradually with the 500ms amplitude.
1.3 data analysis and statistics
Primary current The data Clampfit 10.0 (U.S. Axon company) measures collection, uses Origin 6.0 data processing softwares (U.S. Microcal Software company) the back data are analyzed to gathering, match and mapping.(x ± s) expression adopts paired t-test to experimental data before and after the administration, P＜0.05 is thought has significant difference with mean ± standard deviation.
2. result
2.1 Chinese medicine composition of the present invention is to the effect of rat myocardial cell film IK1
Keep current potential (Vh)-40mV, command potential-120mV～0mV, step 10mV clamps down on time 400ms, and stimulus frequency 0.2Hz can record the inward electric current of a quick active, no obvious inactivation (seeing Fig. 2 A) in 400ms on the single ventricular muscle cell of rat.This electric current can be by 1mmol/L BaCl
2Blocking-up shows that this electric current is I fully
K1I
K1Reduce with depolarization to composition in the electric current, reversal potential pact-40mV has the inward rectification characteristic.Dissolve 0.5% solution that Chinese medicinal composition capsules dry powder of the present invention is mixed with the outer liquid of potassium, to I
K1Inhibitory action (seeing Fig. 2 B) is arranged.The preceding average peak electric current density of medication is-10.78 ± 1.80 (pA/pF) during-100mV, and the average peak electric current density is-7.18 ± 2.05 (pA/pF) after the medication, and average suppression ratio is 33.1 ± 16.85% (n=11, P＜0.05).With electric current density amplitude under each pulse to the corresponding membrane current potential map the I-V curve.Medicine all reduces I on each command voltage level
K1Electric current density, but do not change the shape (seeing Fig. 2 C) of reversal potential and curve basically.After the administration, clamp down on that in difference the IK1 electric current is suppressed, show as on electric current density-voltage curve and move, but upset current potential and rectification property are not had appreciable impact.
2.2 Chinese medicine composition of the present invention is to rat myocardial cell film I
ToEffect
2.2.1 Chinese medicine composition of the present invention is to I
ToThe influence of current-voltage (I-V) curve
The inside and outside liquid of service recorder cell potassium channel is kept current potential (Vh)-90mV, gives earlier-the preceding stimulation of 40mV20ms, give again-40mV～+ depolarization of 60mV stimulates, and step 10mV clamps down on time 400ms, stimulus frequency 0.2Hz.Record export-oriented potassium current in rat ventricular myocytes and comprise two kinds of compositions: a kind of is the transient current (I of quick active and deactivation
To), electric current is " A " type, and peak shape is sharp-pointed, begins to activate from 0mV, and electric current peaks about 10ms, and rapid afterwards inactivation is in 200ms Nei Jibenda stable state.It activates and inactivation all is voltage and time dependence.This electric current can be blocked by the 4-AP of 2mM fully, shows that this electric current is I
ToAnother kind of composition is follow current (I
Maintained), begin to activate from-10mV, in-10～60mV scope, increase with voltage and (to see Fig. 3 A, C).With electric current density amplitude under each pulse to the corresponding membrane current potential map the I-V curve.Deduct with the peak point current amplitude and to keep electric current and obtain transient current, be i.e. I
To0.5% capsule dry powder solution of the present invention is to I
ToElectric current has inhibitory action (seeing Fig. 3 B), under 0～60mV test voltage, shows as the decline of peak point current, and the I-V curve moves down.Average current density at 60mV is reduced to-10.02 ± 3.93 (pA/pF) from-19.82 ± 7.10 (pA/pF), and average suppression ratio is 50.60 ± 10.77% (n=6, P＜0.05) (seeing Fig. 3 D).To I
ToThe inactivation of electric current partly carries out match with the single index equation, can obtain the time constant (τ) of time dependence inactivation.Chinese medicine composition of the present invention can quicken the inactivation (see figure 4) of electric current, and the τZhi before and after the medication is respectively 29.06 ± 4.66 and 21.44 ± 3.12 (n=6, P＜0.05).
2.2.2 Chinese medicine composition of the present invention is to I
ToThe influence of stable state inactivation curve
Record I
ToThe stimulation protocol of stable state inactivation: keep voltage-90mV, give 400ms preceding stimulation, clamp down on then at 60mV 300ms record I from-120mV to 60mV step 10mV
ToElectric current, and relatively change before and after the medication (Fig. 5 A, B).The inactivation that from the map of current of drawing, can see outward current is divided into two processes, at first is the inactivation of keeping electric current, and inactivation voltage is lower, is the inactivation of peak current then, and inactivation voltage will be higher than the former.I
ToAmplitude by peak current and test pulse terminal measure keep the difference decision (Fig. 5 C) between electric current.Each current amplitude of standardization, with relative electric current to each transmembrane potential map the stable state inactivation curve. and with Boltzmann equation I/Imax=1/{1+exp ((Vm-V
1/2)/k) } half inactivation voltage (V is obtained in match
1/2) and inactivation curve slope factor (k) (Fig. 5 D).0.5% capsule dry powder solution of the present invention can make I
ToThe stable state inactivation curve moves to left, and it is big that slope becomes.V1/2 before and after the medication is respectively-15.67 ± 2.52mV and-26.45 ± 3.88mV, and k value becomes 6.38 ± 2.02 (n=7, P＜0.05) (see figure 5) from 3.41 ± 0.67.
2.2.3 Chinese medicine composition of the present invention is to I
ToThe influence of recovery curve behind the inactivation
The employing dipulse stimulates, and keeps voltage-90mV, and successively giving two depolarizations then stimulates P1 to the depolarization that 60mV continues 200ms, and P2, its interval Δ t increase successively and be made as 1,3,5 respectively; 7,10,15,20,30,40,60; 90,120,150,180,210,250,300 (ms).The corresponding peak current amplitude I of record P2.With I/Imax Δ t is made recovery curve behind the stable state inactivation.With the be restored time constant (τ) of curve of single index equation model curve.Can be when drug level 0.5% so that extend to 18.52 ± 3.76 (n=5, P＜0.05) (see figure 6) from 12.86 ± 0.31 recovery time.
2.2 Chinese medicine composition of the present invention is to the myocyte I of guinea-pig ventricular
kEffect
Fig. 7 A is at V
H=-40mV, step 10mV progressively depolarization continue 5s to 60mV, and the single myocyte of guinea-pig ventricular, the voltage of record relies on and the activated outward current I of time-dependent
KChinese medicine composition of the present invention is to I
KElectric current has voltage-dependent inhibitory action (Fig. 7 C).With V
TThe I of=50mV record
KBe observation index, when drug level 0.5%, can make tail current peak current density decline 30.77 ± 1.11% (n=5, p＜0.05).Fig. 8 A, B are the activated in time I with envelope stimulation protocol record
KTail current, and medicine is to the activated I of time dependence
kInhibitory action.
The I that finds at present
ToComprise two types, a kind of for responsive to the insensitive I of cellular calcium to 4 amido pyridines
To1, another kind relies on for calcium and can be by caffeine and Co
2+The I of blocking-up
To2In this research, contain the calcium chelating agent EGTA (10mmol/L) of high concentration in the electrode solution, contain 0.15mmolL in the perfusate
-1Calcium blockers CdCl
2, thereby the moment extroversion potassium current of record does not comprise Ito in this research
2Composition.We observe Chinese medicine composition of the present invention to I in test
ToThe obvious suppression effect is arranged, reduce I
ToCan be through influencing 1 phase multipole of action potential, especially dog, rat and the mankind etc. contains I
ToBigger kind, and APD is prolonged.In addition, I
ToAlso be the main electric current that causes striding myocardial wall multipole inhomogeneity, suppress this electric current wall multipole inhomogeneity is striden in minimizing, reduce and to stride the turn back formation of microcircuit of wall, avoid ARR generations such as torsade de pointes.Also do not have special in the antiarrhythmic drug of clinical practice at present to I
To1The medicine of passage.
In this research, we have observed medicine to I with the single ventricular muscle cell of Cavia porcellus
KThe effect of electric current.The I of Cavia porcellus
KElectric current has quick active and slowly activates two kinds of compositions, and the tail current that we write down after 5 seconds with test pulse is as observation index, and this has mainly represented I
KIn slow activated composition (I
KS), when the rhythm of the heart is accelerated, be I in fact
KSIn process of repolarization, play a major role.We see in test drug level be 0.5% o'clock to I
KInhibitory action is arranged, and this will cause that APD prolongs, and helps medicine and when tachycardia, brings into play antiarrhythmic effect.
In this test, also observe medicine to I
K1The interior of electric current has inhibitory action to composition, but do not change the upset current potential and the rectification characteristic of passage, slightly increases the export-oriented composition of electric current.Though compare this effect there was no significant difference before and after the medication, increase I
K1The export-oriented composition of electric current possibly make action potentials of cells 3 additions reply immediately the utmost point, helps stabilizing cell membrane, eliminates early after depolarization, and the arrhythmia that trigger mechanism is caused has inhibitory action.
In sum, with 5% solution of capsule dry powder of the present invention preparation, the mode that can voltage relies on suppresses the inward rectification potassium current, instantaneous export-oriented potassium current, and Delayed Rectifier Potassium Current.Through irritability that reduces myocardial cell and the process of repolarization that suppresses myocardial cell AP, prolong APD and bring into play antiarrhythmic effect.
Claims (8)
1. the application of Chinese medicine composition in the myocardium potassium-channel dysfunctional antiarrhythmic medicament of preparation treatment, this Chinese medicine composition is processed by following bulk drugs:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
2. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is processed by following bulk drugs:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
3. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is processed by following bulk drugs:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
4. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is processed by following bulk drugs:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
5. like each described application among the claim 1-4, it is characterized in that the active component of this Chinese medicine composition is processed by the following step:
A) people participates in 70% alcohol reflux three times, and merge extractive liquid, filters, and concentrates oven dry, the fine powder that is ground into;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters spissated extractum;
C) fine powder that is broken into of Eupolyph aga sinesis Walker;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decocte with water 2 times, merge extractive liquid,, spissated extractum;
E) with step b) and d) merging of gained extractum, the fine drug powder of adding step c) gained, oven dry is ground into fine powder, adds step a) gained fine drug powder, and mixing promptly gets this Chinese medicine composition active component.
6. like each described application among the claim 1-4, it is characterized in that said Chinese medicine composition is a kind of in capsule, tablet, electuary, powder or the oral liquid formulations.
7. like each described application among the claim 1-4, it is characterized in that this Chinese medicine composition suppresses myocardial cell membrane inward rectification potassium current, instantaneous export-oriented potassium current, and Delayed Rectifier Potassium Current with the mode that voltage relies on; This Chinese medicine composition reduces the irritability and the process of repolarization that suppresses the myocardial cell membrane action potential of myocardial cell through the adjusting to the myocardial cell membrane potassium channel; Prolong the myocardial cell action potential duration, APD.
8. like each described application among the claim 1-4, it is characterized in that said arrhythmia is supraventricular arrhythmia or ventricular tachycardia or ventricular flutter or ventricular fibrillation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100030399A CN101234169B (en) | 2007-02-01 | 2007-02-01 | Application of Chinese medicine composition in preparing medicament for adjusting cardiac muscle cell potassium ion channel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100030399A CN101234169B (en) | 2007-02-01 | 2007-02-01 | Application of Chinese medicine composition in preparing medicament for adjusting cardiac muscle cell potassium ion channel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101234169A CN101234169A (en) | 2008-08-06 |
| CN101234169B true CN101234169B (en) | 2012-05-23 |
Family
ID=39918236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100030399A Active CN101234169B (en) | 2007-02-01 | 2007-02-01 | Application of Chinese medicine composition in preparing medicament for adjusting cardiac muscle cell potassium ion channel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101234169B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101298787B1 (en) * | 2008-07-23 | 2013-08-22 | 허베이 이링 메디슨 리서치 인스티튜트 코오포레이션 리미티드 | A pharmaceutical composition for regulating the potassium channel in cardiac muscle cell and its preparation method and its uses |
| CN101683458B (en) * | 2008-09-23 | 2012-09-05 | 河北以岭医药研究院有限公司 | Application of a traditional Chinese medicine composition in preparation of medicament for treating vertigo |
| CN105055467B (en) * | 2015-08-11 | 2019-05-03 | 河北工业大学 | The mixture of styrax and cell bath and its application in inhibiting Kir2.1 inward current |
| CN104997819B (en) * | 2015-08-11 | 2018-10-12 | 河北工业大学 | Storax and application of the cell bath mixture in terms of inhibiting Kir2.1 outward currents |
| CN105738458A (en) * | 2016-02-22 | 2016-07-06 | 中山大学中山眼科中心 | Measuring method for cell potential of bioengineering retina nerve scaffold |
| CN105943605A (en) * | 2016-06-29 | 2016-09-21 | 山东省科学院生物研究所 | Application of Danhong injection as terfenadine heart adverse effect antagonist |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1483148A (en) * | 2000-10-26 | 2004-03-17 | �����ɷ� | Method and apparatus for determining an error estimate in a hybrid position determination system |
-
2007
- 2007-02-01 CN CN2007100030399A patent/CN101234169B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1483148A (en) * | 2000-10-26 | 2004-03-17 | �����ɷ� | Method and apparatus for determining an error estimate in a hybrid position determination system |
Non-Patent Citations (4)
| Title |
|---|
| 吴以岭.神经肌肉类疾病的中医药治疗.《药物与人》.1998,第11卷(第2期),全文. * |
| 杨萍 等.中药制剂—肌萎灵注射液对神经干细胞的促分化作用.《神经解剖学杂志》.2005,第21卷(第2期),全文. * |
| 王继明 等.肌萎灵注射液对运动神经元保护作用的实验研究.《首届国际络病学大会论文集》.2005,全文. * |
| 谷春华 等.参松养心胶囊对冠心病室性早搏疗效及心脏自主神经功能的影响.《中国中西医结合杂志》.2005,第25卷(第9期),全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101234169A (en) | 2008-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101234169B (en) | Application of Chinese medicine composition in preparing medicament for adjusting cardiac muscle cell potassium ion channel | |
| CN1899400B (en) | A detection method for an injection whose raw material medicine is composed of ginseng and aconite | |
| CN101116722A (en) | Pharmaceutical formulations with the raw material containing panax, ophiopogon root and schisandra fruit, processes for their preparation, the raw material and the quality control method for the prepa | |
| CN102908583A (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation method, quality detection method and application of composition | |
| US11160841B2 (en) | Method of treating a disease associated with potassium ion channel | |
| CN103006838A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| KR101298787B1 (en) | A pharmaceutical composition for regulating the potassium channel in cardiac muscle cell and its preparation method and its uses | |
| CN103006769A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101143157A (en) | Tyrosol and tyrosol bypass salidroside plant extraction and preparation and use thereof | |
| CN103385995B (en) | Traditional Chinese medicine compound for treating arrhythmia and preparation method thereof | |
| CN103860565B (en) | Medicinal composition for treating diabetes hepatic fibrosis | |
| CN113244351A (en) | Traditional Chinese medicine composition for treating coronary heart disease and preparation method and application thereof | |
| CN104622932A (en) | Traditional Chinese medicine for treating myocardial ischemia and preparation method, detection method and application thereof | |
| CN101632726B (en) | Application of Chinese medicinal composition in preparing medicament for treating blood vessel micro-embolization | |
| CN100486615C (en) | Chinese traditional medicine preparation for treating coronary heart disease and angina pectoris and preparation method thereof | |
| CN1081465C (en) | Rhodiola rosea injection for treating angina pectoris of coronary heart disease | |
| RU2463070C1 (en) | Pharmaceutical composition for potassium channel regulation in myocardial cell, method for preparing and using it | |
| CN109303785A (en) | A kind of application of lobetyolin's similar compound in preparation treatment arrhythmia cordis drug | |
| CN104435067B (en) | A kind of Cortex Eucommiae components composition and preparation thereof with myocardium protecting action | |
| CN102178751B (en) | Brain clearing and pain relieving preparation | |
| CN102988478A (en) | Traditional Chinese medicine combination for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101455658A (en) | Use of salvianolic acid A and medicine composition thereof from Salia miliiorrhiza Bge. | |
| CN103961428B (en) | A kind of detection method of the Chinese medicinal composition preparation with promoting flow of QI and blood effect | |
| CN103933340B (en) | A kind of application of Chinese medicine composition in the drug of preparation treatment pneumoconiosis | |
| CN102293929B (en) | Chinese medicine composition for treating arrhythmia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |